Summary & Overview
HCPCS J9209: Mesna Injection, 200 mg
HCPCS Level II code J9209 denotes a 200 mg injectable dose of mesna, a uroprotective agent administered alongside certain chemotherapies to prevent hemorrhagic cystitis. Nationally, accurate coding and appropriate billing of supportive oncology drugs like mesna are important for facility workflows, payer adjudication, and chemotherapy regimen accounting. This analysis covers payment and coverage considerations across major national payers.
Key payers included are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how J9209 is classified and billed, common payer coverage patterns, and operational considerations for infusion settings such as hospital outpatient departments and infusion clinics. The publication also summarizes typical documentation needs and what benchmarks and policy updates to watch for regarding billing supportive oncology agents.
The report is intended for billing managers, oncology clinic administrators, and policy staff seeking a concise reference on coding J9209, payer scope, and the clinical context in which mesna is administered. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9209 represents an injectable formulation of mesna, supplied in increments of 200 mg per billing unit. Mesna is an agent used to reduce the risk of urothelial toxicity associated with certain chemotherapeutic agents; billing for J9209 reflects administration of the specified dosage of the drug.
-
Service type: Injectable drug administration
-
Typical site of service: Hospital outpatient department, infusion center, or clinic where parenteral chemotherapy and supportive agents are administered
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 58-year-old female receiving cyclophosphamide-containing chemotherapy for high-grade urothelial carcinoma presents for scheduled supportive care. Mesna is indicated to prevent hemorrhagic cystitis from ifosfamide or cyclophosphamide metabolites. The medication billed as J9209 (Injection, mesna, 200 mg) is prepared by pharmacy, verified for dose by weight and chemotherapy protocol, and administered intravenously in the outpatient oncology infusion center. Clinical workflow: oncology team orders mesna on the chemotherapy order set; pharmacy compounds and labels the J9209 vial(s); nursing verifies orders, performs pre-infusion safety checks, obtains venous access, and administers the IV bolus or infusion per protocol timing relative to the cytotoxic agent; nursing documents lot number, dose, route, and any immediate reactions. Billing captures the number of 200 mg units administered; appropriate service modifiers are appended as indicated by payer rules and clinical circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JZ | Drug amount administered - no wastage | When entire drug vial(s) were administered with no discard |